Science / The nutrients
SAMe and Depression
SAMe, or S-adenosylmethionine, is the body’s principal methyl donor and a central agent in the one-carbon cycle. In depression it has been studied mainly as an addition to antidepressant treatment, and a systematic review in the American Journal of Psychiatry concluded that current evidence supports the adjunctive use of SAMe, methylfolate and omega-3 with antidepressants. In Hedonia it is chosen to work with the other two nutrients rather than on its own.
Why this page is framed this way
This page was deliberately built as the case for why SAMe is in the formulation, rather than as a summary of the trial record for SAMe used on its own. The distinction matters: SAMe is not in Hedonia as a standalone agent, and describing it as though it were understates it. The organising sources are the WFSBP and CANMAT guidelines, the Sarris 2016 systematic review, the Cochrane finding for SAMe added to an SSRI, and the divergent-pathways rationale in Tobin 2024.
What is SAMe?
SAMe is made in the body rather than obtained from food in any meaningful quantity, and its synthesis draws on the amino acid methionine and on folate. [1] It is the body’s principal methyl donor, meaning it supplies the methyl groups used in a wide range of biochemical reactions. Along with folate and methylfolate it belongs to what researchers call the one-carbon cycle, which is the set of linked reactions that carry and transfer those methyl groups. [2]
How is SAMe thought to work?
Through methylation. The American Journal of Psychiatry review sets out the mechanism directly: the one-carbon cycle agents are critical in the methylation of monoamines, and SAMe in particular may improve depressed mood through enhanced methylation of catecholamines, increased serotonin turnover, reuptake inhibition of norepinephrine, enhanced dopaminergic activity and increased phosphatidylcholine conversion. [2] The same review notes that anti-inflammatory properties are well demonstrated for both SAMe and EPA, which is one of the points at which the two nutrients meet. [2]
Is SAMe supported for use alongside an antidepressant?
Yes. A systematic review and meta-analyses of adjunctive nutraceuticals in the American Journal of Psychiatry concluded that current evidence supports the adjunctive use of SAMe, methylfolate and omega-3 with antidepressants to reduce depressive symptoms, and found primarily positive results in replicated studies for SAMe. [2] The 2022 clinician guidelines from the WFSBP and CANMAT include SAMe among the nutraceuticals assessed for unipolar depression. [3] The Cochrane review of SAMe in adults found that SAMe was superior to placebo when added to an SSRI, with a mean difference of 3.90 points in depressive symptoms from baseline to end of treatment (95% CI 0.87 to 6.93, p = 0.01), from a study of 73 participants. [4][5]
Why is SAMe combined with EPA and L-methylfolate rather than used alone?
Because the three act on different pathways, and the argument for combining them is that together they cover ground that none of them covers alone. This is the rationale set out in Tobin, Vuckovic and Sarris in Nutrients in 2024, which is where the case for targeting divergent pathways in the nutritional management of depression is made. [6] SAMe and L-methylfolate both sit on the one-carbon cycle but act at different points within it, whilst EPA works through inflammation and cell membrane composition. [2][6] The American Journal of Psychiatry review makes the same case in general terms, observing that a formulation combining several of these agents may provide an array of antidepressant action beyond that of isolated approaches. [2] SAMe is in Hedonia as a synergistic partner to the omega-3 and methylfolate, rather than as a standalone agent.
Does SAMe need medical supervision?
Yes, and this is worth stating plainly. SAMe should be discussed with a doctor by anyone diagnosed with bipolar disorder, anyone taking medicines that affect serotonin, anyone taking levodopa, and anyone who is pregnant or nursing. [1][7] Hedonia is a medical food intended for use under medical supervision for exactly this kind of reason: the supervision is part of the product’s design rather than a formality attached to it.
Where Hedonia sits
Four Hedonia capsules a day provide 1,200 mg of SAMe, as Adonat® Premium SAMe, alongside 1,440 mg of EPA omega-3 and 15 mg of L-methylfolate. The three are combined deliberately, on the divergent-pathways rationale set out in the 2024 Nutrients review. Hedonia is a medical food for the dietary management of the nutritional requirements associated with depression, intended for use under medical supervision alongside a physician-directed treatment plan.
References
- Merck Manual Professional Edition. S-Adenosyl-L-Methionine. Full review July 2025. Merck Manual
- Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, Ng CH. Adjunctive nutraceuticals for depression: a systematic review and meta-analyses. Am J Psychiatry. 2016;173(6):575-587. PMID 27113121. PubMed
- Sarris J, Ravindran A, Yatham LN, et al. WFSBP and CANMAT Taskforce clinician guidelines. World J Biol Psychiatry. 2022;23(6):424-455. PMID 35311615. PubMed
- Galizia I, Oldani L, Macritchie K, Amari E, Dougall D, Jones TN, et al. S-adenosyl methionine (SAMe) for depression in adults. Cochrane Database Syst Rev. 2016;10(10):CD011286. PMID 27727432. Cochrane
- Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder. Am J Psychiatry. 2010;167(8):942-948. PMID 20595412. PubMed
- Tobin D, Vuckovic A, Sarris J. Targeting divergent pathways in the nutritional management of depression. Nutrients. 2024;16(16):2806. PMID 39203943. Open access
- National Center for Complementary and Integrative Health. S-Adenosyl-L-Methionine (SAMe): In Depth. National Institutes of Health. NCCIH